Dan Cole

Coherex Medical, Inc. designs, develops, and markets catheter-based technologies for the treatment of structural heart defects. It offers WaveCrest device that is placed in the opening of the left atrial appendage to reduce complications associated with other device types, as well as simplifies the implant procedures. The company was founded by Brian K. Whisenant and Clark C. Davis in 2003 and is headquartered in Salt Lake City, UT.

Coherex Medical, Inc. designs, develops, and markets catheter-based technologies for the treatment of structural heart defects. It offers WaveCrest device that is placed in the opening of the left atrial appendage to reduce complications associated with other device types, as well as simplifies the implant procedures. The company was founded by Brian K. Whisenant and Clark C. Davis in 2003 and is headquartered in Salt Lake City, UT.

Coherex Medical, Inc. designs, develops, and markets catheter-based technologies for the treatment of structural heart defects. It offers WaveCrest device that is placed in the opening of the left atrial appendage to reduce complications associated with other device types, as well as simplifies the implant procedures. The company was founded by Brian K. Whisenant and Clark C. Davis in 2003 and is headquartered in Salt Lake City, UT.

Coherex Medical, Inc. designs, develops, and markets catheter-based technologies for the treatment of structural heart defects. It offers WaveCrest device that is placed in the opening of the left atrial appendage to reduce complications associated with other device types, as well as simplifies the implant procedures. The company was founded by Brian K. Whisenant and Clark C. Davis in 2003 and is headquartered in Salt Lake City, UT.

Direct Flow Medical, Inc. develops transcatheter heart valve technologies. It explores application of its technology beyond the aortic valve, to the mitral valve, and other valve anatomy. The firm’s Transcatheter Aortic Valve System is indicated for the treatment of patients with severe aortic stenosis, who are at risk for surgical aortic valve replacement. The company's system incorporates a polymer frame, which is expanded using pressurized saline and contrast for placement, assessment and repositioning. Direct Flow Medical was founded by Gordon B. Bishop and Randall T. Lashinski in June 2004 and is headquartered in Santa Rosa, CA.

Direct Flow Medical, Inc. develops transcatheter heart valve technologies. It explores application of its technology beyond the aortic valve, to the mitral valve, and other valve anatomy. The firm’s Transcatheter Aortic Valve System is indicated for the treatment of patients with severe aortic stenosis, who are at risk for surgical aortic valve replacement. The company's system incorporates a polymer frame, which is expanded using pressurized saline and contrast for placement, assessment and repositioning. Direct Flow Medical was founded by Gordon B. Bishop and Randall T. Lashinski in June 2004 and is headquartered in Santa Rosa, CA.

Coherex Medical, Inc. designs, develops, and markets catheter-based technologies for the treatment of structural heart defects. It offers WaveCrest device that is placed in the opening of the left atrial appendage to reduce complications associated with other device types, as well as simplifies the implant procedures. The company was founded by Brian K. Whisenant and Clark C. Davis in 2003 and is headquartered in Salt Lake City, UT.

Direct Flow Medical, Inc. develops transcatheter heart valve technologies. It explores application of its technology beyond the aortic valve, to the mitral valve, and other valve anatomy. The firm’s Transcatheter Aortic Valve System is indicated for the treatment of patients with severe aortic stenosis, who are at risk for surgical aortic valve replacement. The company's system incorporates a polymer frame, which is expanded using pressurized saline and contrast for placement, assessment and repositioning. Direct Flow Medical was founded by Gordon B. Bishop and Randall T. Lashinski in June 2004 and is headquartered in Santa Rosa, CA.

Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA.

Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA.

Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA.

Direct Flow Medical, Inc. develops transcatheter heart valve technologies. It explores application of its technology beyond the aortic valve, to the mitral valve, and other valve anatomy. The firm’s Transcatheter Aortic Valve System is indicated for the treatment of patients with severe aortic stenosis, who are at risk for surgical aortic valve replacement. The company's system incorporates a polymer frame, which is expanded using pressurized saline and contrast for placement, assessment and repositioning. Direct Flow Medical was founded by Gordon B. Bishop and Randall T. Lashinski in June 2004 and is headquartered in Santa Rosa, CA.

Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA.

Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA.

Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA.

Coherex Medical, Inc. designs, develops, and markets catheter-based technologies for the treatment of structural heart defects. It offers WaveCrest device that is placed in the opening of the left atrial appendage to reduce complications associated with other device types, as well as simplifies the implant procedures. The company was founded by Brian K. Whisenant and Clark C. Davis in 2003 and is headquartered in Salt Lake City, UT.

Direct Flow Medical, Inc. develops transcatheter heart valve technologies. It explores application of its technology beyond the aortic valve, to the mitral valve, and other valve anatomy. The firm’s Transcatheter Aortic Valve System is indicated for the treatment of patients with severe aortic stenosis, who are at risk for surgical aortic valve replacement. The company's system incorporates a polymer frame, which is expanded using pressurized saline and contrast for placement, assessment and repositioning. Direct Flow Medical was founded by Gordon B. Bishop and Randall T. Lashinski in June 2004 and is headquartered in Santa Rosa, CA.

Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA.

Direct Flow Medical, Inc. develops transcatheter heart valve technologies. It explores application of its technology beyond the aortic valve, to the mitral valve, and other valve anatomy. The firm’s Transcatheter Aortic Valve System is indicated for the treatment of patients with severe aortic stenosis, who are at risk for surgical aortic valve replacement. The company's system incorporates a polymer frame, which is expanded using pressurized saline and contrast for placement, assessment and repositioning. Direct Flow Medical was founded by Gordon B. Bishop and Randall T. Lashinski in June 2004 and is headquartered in Santa Rosa, CA.

Coherex Medical, Inc. designs, develops, and markets catheter-based technologies for the treatment of structural heart defects. It offers WaveCrest device that is placed in the opening of the left atrial appendage to reduce complications associated with other device types, as well as simplifies the implant procedures. The company was founded by Brian K. Whisenant and Clark C. Davis in 2003 and is headquartered in Salt Lake City, UT.

Direct Flow Medical, Inc. develops transcatheter heart valve technologies. It explores application of its technology beyond the aortic valve, to the mitral valve, and other valve anatomy. The firm’s Transcatheter Aortic Valve System is indicated for the treatment of patients with severe aortic stenosis, who are at risk for surgical aortic valve replacement. The company's system incorporates a polymer frame, which is expanded using pressurized saline and contrast for placement, assessment and repositioning. Direct Flow Medical was founded by Gordon B. Bishop and Randall T. Lashinski in June 2004 and is headquartered in Santa Rosa, CA.

Coherex Medical, Inc. designs, develops, and markets catheter-based technologies for the treatment of structural heart defects. It offers WaveCrest device that is placed in the opening of the left atrial appendage to reduce complications associated with other device types, as well as simplifies the implant procedures. The company was founded by Brian K. Whisenant and Clark C. Davis in 2003 and is headquartered in Salt Lake City, UT.

Direct Flow Medical, Inc. develops transcatheter heart valve technologies. It explores application of its technology beyond the aortic valve, to the mitral valve, and other valve anatomy. The firm’s Transcatheter Aortic Valve System is indicated for the treatment of patients with severe aortic stenosis, who are at risk for surgical aortic valve replacement. The company's system incorporates a polymer frame, which is expanded using pressurized saline and contrast for placement, assessment and repositioning. Direct Flow Medical was founded by Gordon B. Bishop and Randall T. Lashinski in June 2004 and is headquartered in Santa Rosa, CA.

Direct Flow Medical, Inc. develops transcatheter heart valve technologies. It explores application of its technology beyond the aortic valve, to the mitral valve, and other valve anatomy. The firm’s Transcatheter Aortic Valve System is indicated for the treatment of patients with severe aortic stenosis, who are at risk for surgical aortic valve replacement. The company's system incorporates a polymer frame, which is expanded using pressurized saline and contrast for placement, assessment and repositioning. Direct Flow Medical was founded by Gordon B. Bishop and Randall T. Lashinski in June 2004 and is headquartered in Santa Rosa, CA.

Coherex Medical, Inc. designs, develops, and markets catheter-based technologies for the treatment of structural heart defects. It offers WaveCrest device that is placed in the opening of the left atrial appendage to reduce complications associated with other device types, as well as simplifies the implant procedures. The company was founded by Brian K. Whisenant and Clark C. Davis in 2003 and is headquartered in Salt Lake City, UT.

Direct Flow Medical, Inc. develops transcatheter heart valve technologies. It explores application of its technology beyond the aortic valve, to the mitral valve, and other valve anatomy. The firm’s Transcatheter Aortic Valve System is indicated for the treatment of patients with severe aortic stenosis, who are at risk for surgical aortic valve replacement. The company's system incorporates a polymer frame, which is expanded using pressurized saline and contrast for placement, assessment and repositioning. Direct Flow Medical was founded by Gordon B. Bishop and Randall T. Lashinski in June 2004 and is headquartered in Santa Rosa, CA.

Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA.

Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA.